Aegirbio AB

Chart & performance

D1W1MN

P/E

—

P/S

167.72

EPS

—

Div yield, %

—

Shrs. gr., 5y

—

Rev. gr., 5y

503.67%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

AegirBio AB (publ) is a diagnostics firm established in 2019 in Lund, Sweden. The company specializes in developing and commercializing tests primarily aimed at monitoring the dosage of biological drugs. Their efforts are concentrated on therapeutic drug monitoring for biologic therapies across various conditions, including multiple sclerosis, different types of cancer, and autoimmune diseases. Among their offerings are moNATor, a pioneering laboratory test designed for dose monitoring in multiple sclerosis for both medical professionals and patients, and Viraspec, a saliva-based test kit for COVID-19 detection.

URL

https://aegirbio.com/

IPO date

Jun 26, 2020

Employees

Domiciled in

Incorporated in

Valuation

No data to show